Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1QZKS)

• Drug Name: NTC-801 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Atrial fibrillation	BC81.3	Discontinued in Phase 1	[1]
Atrial flutter	BC81.2Z	Discontinued in Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM1QZKS

Molecule-Related Drug Atlas

Drug(s) Targeting Potassium channel unspecific (KC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[3]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[3]
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[4]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[3]
Amifampridine	DMK08L3	LambertEaton myasthenic syndrome	8C62	Approved	[5]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[3]
Pinacidil	DMRADYL	High blood pressure	BA00	Approved	[3]
Dalfampridine	DMM0PDO	Multiple sclerosis	8A40	Approved	[6]
Ibutilide	DMKXY2R	Atrial fibrillation	BC81.3	Approved	[3]
Diazoxide	DML1538	Congenital hyperinsulinism	5A4Y	Approved	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Inhibitor	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023917)
• [2] Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs. J Cardiovasc Pharmacol. 2014 May;63(5):421-7.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [5] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [6] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.